突变型p53和CD44v6基因产物在肾肿瘤表达研究

目的 探讨突变型p53和CD44v6基因表达产物与肾肿瘤临床行为的关系.方法 对98例肾肿瘤石蜡包埋标本,采用免疫组化SP法分别测定突变型p53和CD44v6基因产物,并对肾癌患者5年生存率随访.结果 突变型p53与肾癌分期、分级无关,在统计学上均无显著性差异(P＞0.05),与5年生存率具有相关性(P＜0.05),突变型p53在肾错构瘤组织中呈阴性表达.CD44v6与肾癌分期、分级及5年生存率相关,在统计学上具有显著性差异(P＜0.05),CD44v6在错构瘤组织中呈阴性表达.结论 突变型p53基因与肾癌发病机制及预后有关,与肾癌恶性程度无关.CD44v6在肾癌发病浸润生长及预后中发挥作用.突变型p53和CD44v6联合检测可能成为评价肾肿瘤临床行为的指标.

Study on expression of mutation p53 and CD44v6 Gene in kidney meoplasms

Objective To study the relationship between the expression of mutation p53 and CD44v6 gene and clinical behaviour of kidney neoplasms. Methods The expression of p53 and CD44v6 gene was examined by immunohistochemical staining in paraffin embeded tissues of kidney neoplasms, Five years survival rates were evaluated clinically, Results No significant relationship is observed between mutation p53 and grade and stage of renal cell carcinoma, Expression of mutation p53 was associated with 5 years survival in renal cell carcinoma, There were significant relationship between expression of CD44v6 gene and the grade and stage of renal cell carcinoma and 5 years survival, The expression of mutation p53 and CD44v6 was negative in renal angioleiomy-olipoma. Conclusion No relationship was observed between mutation p53 and the degree of the malignancy. Expression of CD44v6 plays an important role in the incidence, growth and prognosis of renal cell carcinoma. Mutation p53 and CD44v6 might serve as a marker in the evaluation of clinical behaviour of kidney neoplasms.